Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies

Research output: Contribution to journalArticle

Standard

Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies. / Goyal, D; Choudhury, Anirban; Lip, Gregory.

In: Current Opinion in Obstetrics and Gynaecology, Vol. 17, No. 1, 01.02.2005, p. 13-20.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{4da93181b68142f1862dd3f7fe44fe62,
title = "Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies",
abstract = "PURPOSE OF REVIEW: Thrombotic complications are a common cause of morbidity and mortality in patients with gynaecological or advanced breast malignancies. There are several manifestations of thromboembolism in these patients, but deep venous thrombosis of the legs is the usual presentation. This review highlights various manifestations of thrombotic complications in these malignancies, and also describes the current evidence base for various forms of thromboprophylaxis. RECENT FINDINGS: Several trials have suggested that low molecular weight heparin therapy is at least as effective as oral anticoagulation for secondary prophylaxis. It has also been suggested that low molecular weight heparin therapy may prolong survival in cancer patients, but this was not shown in the results of one recently published placebo-controlled randomized trial. SUMMARY: Primary thromboprophylaxis in cancer should be individualized and considered according to the risk category of each patient. Low molecular weight heparin therapy can be used for secondary thromboprophylaxis in patients with breast or gynaecological malignancy. However, more studies are needed to substantiate their acceptance in cancer patients.",
author = "D Goyal and Anirban Choudhury and Gregory Lip",
year = "2005",
month = feb,
day = "1",
language = "English",
volume = "17",
pages = "13--20",
journal = "Current Opinion in Obstetrics and Gynaecology",
issn = "1040-872X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Thrombotic complications and thromboprophylaxis in breast and gynaecological malignancies

AU - Goyal, D

AU - Choudhury, Anirban

AU - Lip, Gregory

PY - 2005/2/1

Y1 - 2005/2/1

N2 - PURPOSE OF REVIEW: Thrombotic complications are a common cause of morbidity and mortality in patients with gynaecological or advanced breast malignancies. There are several manifestations of thromboembolism in these patients, but deep venous thrombosis of the legs is the usual presentation. This review highlights various manifestations of thrombotic complications in these malignancies, and also describes the current evidence base for various forms of thromboprophylaxis. RECENT FINDINGS: Several trials have suggested that low molecular weight heparin therapy is at least as effective as oral anticoagulation for secondary prophylaxis. It has also been suggested that low molecular weight heparin therapy may prolong survival in cancer patients, but this was not shown in the results of one recently published placebo-controlled randomized trial. SUMMARY: Primary thromboprophylaxis in cancer should be individualized and considered according to the risk category of each patient. Low molecular weight heparin therapy can be used for secondary thromboprophylaxis in patients with breast or gynaecological malignancy. However, more studies are needed to substantiate their acceptance in cancer patients.

AB - PURPOSE OF REVIEW: Thrombotic complications are a common cause of morbidity and mortality in patients with gynaecological or advanced breast malignancies. There are several manifestations of thromboembolism in these patients, but deep venous thrombosis of the legs is the usual presentation. This review highlights various manifestations of thrombotic complications in these malignancies, and also describes the current evidence base for various forms of thromboprophylaxis. RECENT FINDINGS: Several trials have suggested that low molecular weight heparin therapy is at least as effective as oral anticoagulation for secondary prophylaxis. It has also been suggested that low molecular weight heparin therapy may prolong survival in cancer patients, but this was not shown in the results of one recently published placebo-controlled randomized trial. SUMMARY: Primary thromboprophylaxis in cancer should be individualized and considered according to the risk category of each patient. Low molecular weight heparin therapy can be used for secondary thromboprophylaxis in patients with breast or gynaecological malignancy. However, more studies are needed to substantiate their acceptance in cancer patients.

M3 - Article

C2 - 15711406

VL - 17

SP - 13

EP - 20

JO - Current Opinion in Obstetrics and Gynaecology

JF - Current Opinion in Obstetrics and Gynaecology

SN - 1040-872X

IS - 1

ER -